Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 7/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.52 |
| ▸ | HTR7 | P34969 | 6/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | HTR2B | P41595 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651622 | 0.91 | KDM4E (0.68) | ALDH1A1KDM4ECASP1KMT2AMEN1 | |
| SCHEMBL13562512 | 0.84 | KMT2A (0.67) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL9120363 | 0.82 | KMT2A (0.83) | ALDH1A1KMT2AMEN1LMNAHSD17B10 | |
| SCHEMBL9121163 | 0.81 | KMT2A (0.81) | ALDH1A1KMT2AMEN1LMNANPC1 | |
| Hydrochloric Acid SCHEMBL9120510 | 0.80 | KMT2A (0.78) | ALDH1A1KMT2AMEN1LMNANPC1 | |
| SCHEMBL22721189 | 0.78 | ALDH1A1 (0.83) | ALDH1A1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL7651823 | 0.76 | HSD17B10 (0.61) | ALDH1A1KDM4ELMNAHSD17B10HTR1A | |
| SCHEMBL11548124 | 0.76 | KMT2A (0.55) | ALDH1A1KDM4ECASP1KMT2AMEN1 | |
| SCHEMBL7654287 | 0.75 | HSD17B10 (0.68) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL7393703 | 0.75 | KMT2A (0.62) | ALDH1A1KDM4EKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000000472-A1 | 5-HT7 RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | ALDH1A1 2592/4885KDM4E 3671/4885CASP1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.